Acceptance stage of loss, 71, 72
Age alaryngeal speech development problems and, 596–597 decision making and, 713 laryngeal carcinoma and, 200 prevalence of oral cancer and, 600 radiation therapy and, 205 AIDS/HIV, 746 AL. See Artificial larynx (AL)
oral articulatory evaluation, 305–306
overarticulation, 561–563
radical surgery and, 603
tracheoesophageal (TE) speech and, 66, 680
Artificial larynx (AL). See also History of Artificial larynx (AL); Verbal communication
acceptability to listener, 134–135
application of term, 19
articulation and, 65–67, 559–563, 578
average communication profile score and, 86
cancer recurrence and, 34
candidacy for, 565
clinical application of, 548–549
communication problems and, 84–85
compared with other types of alaryngeal speech, 61–62
consistency of voicing, 670
current improvement for speech using, 582–588
definition of, 549–551
dentures and, 565
development of, 549–551
diagram of, 586
evaluation of, 670, 672–673, 674
failure with, 79
fundamental frequency and, 119–121
future of, 587–588
general principles of, 35–36
goals in use of, 556–564, 672–673
hearing loss and, 368
illustrations of, 41–42, 44–48
implant devices, 579–580, 587
intelligibility and, 82, 83, 566, 578, 581, 582, 584
intraoral device, 554–555, 578
limitations of speech production and, 580–582
long-term effects of use of, 106–107
loudness and, 67–68, 121–122, 581
mouth-type devices, 576–579
neck-type devices, 551–554, 574–576, 577, 585
nonverbal behaviors and, 564
on–off control of, 65, 563–564
oral reading rate for, 83
overarticulation and, 561–563
overview of, 35–36, 79, 547–548, 573
pitch and, 581
placement and, 63, 557–561, 574
preference rate for, 80–81
quality of life (QOL) and, 727
rehabilitation outcomes and, 566–567
selection of, 555
signal transmission and, 559
speech acceptability and, 550–551
speech rate and, 69–70, 561–563
statistics on usage of, 61–62
success rates of, 548
tissue irritation and, 34
training in, 556–564
types of, 551–554, 573–580
Artificial voice boxes, 33
ASHA. See American Speech-Language-Hearing Association (ASHA)
Aspiration
near-total laryngectomy (NTL) and, 230
supracricoid partial laryngectomy with reconstruction (SCPL) and, 231
supraglottic laryngectomy (SGL) procedure and, 227–228
swallowing disorders and, 329
Assessment
of artificial larynx, 670, 672–673, 674
baseline and, 682–684
of esophageal speech (ES), 670, 673, 675, 679
goals for rehabilitation and, 670–672
oral communication assessment, 299–300, 669
oral–motor and communication function assessment, 301–306
of patients needing maxillofacial prosthodontics, 307–308
performance accuracy and, 687
presurgical dental assessment and management, 282, 286
of quality of life (QOL), 699–703, 718–722
TE speech and, 615, 679–680, 681
TEP procedure and, 484–485
Aurex Corporation, 36, 44, 575
Autonomy, 707–708, 712
Bargaining stage of loss, 71
Behavioral goals, 672
Belching, 407
Bell Telephone Laboratories, 35, 36, 39, 40, 46
Beneficence, 707
Biopsy, 26, 28
Biopsychosocial model of treatment, 7–9, 724–725, 743–745
Bivona, 494, 495, 575
Blom–Singer duckbill voice prosthesis, 496, 604
Blom–Singer Humidifilter, 497
Blom–Singer indwelling voice prosthesis, 483, 494
Boston University, 176
Botox, 490, 536, 538, 608, 613
Bronchodilators, 516
Caffeine, 205
Canadian Cancer Society, 633, 634, 651, 660
Candida, 455, 467–468, 474, 493, 618–619
Candidiasis, 204
Carcinoma in situ, 199
CAT. See Computer assisted tomography (CAT)
Cellular Pathology, 28
Cervical rotation flaps, 241–242
Chemotherapy
  limitations of, 266
  overview of, 202–204, 274
  side effects of, 157, 318
  vocal tract effects of, 204–205
CHEP. See Cricohyoidoepiglottopexy (CHEP)
Children, 365
CHP. See Cricohyoidopexy (CHP)
Cleft Palate Clinic, 45
Clinician’s Guide to Alaryngeal Speech Therapy (Graham), 420
Cognitive-mental status, 599
Communication. See also Alaryngeal speech; Verbal communication; Vocal intelligibility; specific types of alaryngeal speech; communication problems, 84–86
communication satisfaction, 98–100
counseling and, 299
“functional communication”, 96
maxillofacial rehabilitation and, 299–306
nonverbal behaviors, 416–418, 424, 424–425, 564, 675
oral–motor and communication function assessment, 301–306
oral reading rate, 82
outcome measures, 306–308
proficiency of, 81–84
social context of, 115
speech–language pathologists and, 300, 307
telephone communication, 84
Communication Effectiveness Index (Lomas), 307
Communication Profile, 85
Computer assisted tomography (CAT), 272
Computerized tomography (CT), 148, 317
Conservation laryngectomy procedures. See also Nonsurgical treatment of laryngeal carcinoma
near-total laryngectomy (NTL), 230–231
overview of, 225
supracricoid partial laryngectomy with reconstruction (SCPL), 231–232
supraglottic laryngectomy, 226–228
vertical partial laryngectomy (VPL), 228–229
voice affect of, 229
Cooper–Rand Artificial larynx (AL), 36, 45, 46
Coughing, 199, 595
Counseling. See also Group treatment models; Peer group support; Speech–language pathologists
children, 365
conversation starters, 375–376
educating patients and families and, 362–363
emotional support and, 356–360
friends, 365–366
grief cycle stages and, 357
homecoming preparation, 369–370
listening and, 358
overview of, 355–356
physical disfigurement and, 361
postoperative inpatient counseling, 368–369, 373
postsurgery outpatient counseling, 370, 374
preoperative counseling, 366–368, 372, 458
pretreatment counseling, 318–319
psychiatric morbidity and, 5
spouses, 363–366
techniques for, 357–360
treatment goals and, 359–360
treatment outcomes and, 100–102, 108
trust establishment and, 360–362
Cricohyoidoepiglottopexy (CHEP), 231-232
Cricohyoidopexy (CHP), 231
Cricopharyngeal spasm, 533–535
CT. See Computerized tomography (CT)

Death and Dying (Kubler–Ross), 70–71
Defect obturation, 275–276, 287–290, 337. See also Prosthetic management
Definitive obturator, 289
Delayed dysphonia, 491–492. See also Dysphonia
Delayed postfitting aphonia, 486
Deltoplectoral flap (DP), 243–245
Denial and isolation, 71–72
Dentistry
  articulation and, 414
dental implants, 282, 285
  for edentulous and mandibulactomized individual, 293–294
  for edentulous individual, 291–292
  implant–supported prosthesis management, 297–299
  for partially edentulous individual, 290–291
  for partially edentulous mandibulectomized individual, 292–293
  radiation and, 318
  rehabilitative dentistry, 277–280
Depression, 71, 72, 641, 649, 710, 711, 724, 744
Diagnosis, 267–272
Disability in America: Toward a National Agenda for Prevention (Pope & Tarlov), 307
Distress. See Psychological issues
Drowning, 595
Dysphagia, 199, 595, 597, 601–602
Dysphonia, 199, 491–492
Dysplasia
  definition of, 199
disease presentation, 173
endoscopic technique and, 178–179
management philosophy, 173–176
vocal outcome and, 179–182

Dyspnea, 22, 199

Early glottic cancer. See also Glottic cancer; Oral
cancer
disease presentation, 173
endoscopic technique and, 178–179
management philosophy, 173–178
vocal outcome and, 179–182

Eating/drinking, 10, 601

Educational materials, 709

Electronic artificial larynx. See Artificial larynx
(AL)

Emotional support, 356–360

Endoscopic technique
laryngeal function and, 188–189
supraglottic cancer and, 185–188
vocal fold atypia and, 178–179
vocal outcome and, 179–182

Epithelioma, 29

ES. See Esophageal speech (ES)

Esophageal insufflation testing, 437–438, 439

Esophageal speech (ES). See also Verbal communica-
tion
acceptability to listener, 134
activity score sheets, 419–421
advantages of, 381–382
air intake and, 386–387, 390–408, 421–425
anatomy and physiology of esophageal speech
methods, 390–393
articulation and, 65–67, 413–415, 422, 675
average communication profile score and, 86
cognitive–mental status and, 599
communication problems and, 84–85
compared with other types of alaryngeal
speech, 61–62
consistency of voicing, 670, 673
descriptive aspects of, 118
disadvantages of, 382
durational measures, 122
factors for consideration in choosing, 382–383
failure in, 383–384, 388–389, 526
feedback and, 389, 419–421
functional assessment of, 670, 673, 675–679
fundamental frequency and, 119–121
glottal fricative and, 415
hearing loss and, 414, 417
hypertonic pharynx and, 409–411
inhalation method and, 392–393, 407–408,
411–412, 413
injection method for obstruents (HMO), 392,
394–402, 412
intelligibility and, 83, 84, 384–385, 673
latency and, 412–413
loudness and, 67–68, 423–424, 675
multidimensional structure of alaryngeal speech
and, 128
nasal resonance and, 415
nonverbal behaviors and, 416–418, 424
obstruents and air intake, 386–387
oral reading rate for, 82, 83
pharyngoesophageal (PE) segment and, 523–
526, 529–534
pitch control, 423
prevalence of use of, 77–79, 381
production levels, 424–425
prognosis for acquisition of, 383–384
pulmonary function and, 600
radiation therapy and, 597–598
speech–language pathologist prejudice toward,
94–95, 103
speech rate and, 382, 415–416, 422, 675
sphincter tension and, 527–528
statistics on usage of, 61–62
training for, 384–386, 388–390, 418–419, 606,
675, 679
vocal intensity and, 121–122
voice consistency and, 408–411
vowel hierarchy and, 387–388

Ethics, 707–708

European Organization for Research and Treatment of
Cancer Core Quality of Life Questionnaire–
Head and Neck Cancer Module (EORTC
QLQ–H&N37; Bjordal Ahlner-Elmqvist),
700

Family. See also Peer group support
counseling overview and, 355–356
descriptive support and, 356–360
group treatment models and, 648, 651
homecoming preparation, 369–370
information delivery to, 362–363
post surgery outpatient counseling, 370, 374
quality of life (QOL) and, 710
rehabilitation success and, 627
Fatigue, 505, 606, 651, 719, 724, 726
Feedback, 389, 419–421, 684–685
Flatulence, 498

Follow up
flow-chart for postsurgery follow up, 271

TEP voice prosthesis troubleshooting and, 483
upper aerodigestive tract malignancy and, 150–
151

Free flap procedures, 167–168
Frequency, 119-121
Friends, 365-366
Fronto-lateral laryngectomy. See Vertical partial laryngectomy (VPL)
Functional Assessment of Cancer Therapy Scale (FACT-G; Cell), 700
Fundamental frequency, 119-121

Gastric pull-up procedure, 245-246, 257
Gastroesophageal (GE) junction, 245
Gastroesophageal reflux, 617-618
GE. See Gastroesophageal (GE) junction
Gender
decision making and, 713
group treatment and, 648
special needs of women, 100–102
women-only support groups, 656
Glottal fricative, 415
Glottic cancer
ey early glottic cancer, 173–182
mid-sized glottic cancer, 183–184
supraglottic cancer, 185–189
Goals for treatment, 359–360
Granuloma, 488, 497–498
Grief cycle, 70–72, 357
Griffin Laboratories, 575
Group treatment models. See also Counseling; Peer group support
attendance and, 647–649, 654
benefits of, 653
clinical issues, 650–651
common features of, 645–651
common personal themes, 649–650
t five levels of, 642
format and content of, 647
head and neck cancer support groups, 655–656
hospital-based laryngectomy support groups, 652–655
individual versus group therapy, 687–688
isolation and, 641, 644–645
new voice clubs, 641–652
objectives of, 646–647
one-to-one peer support, 656
organizational strategies for, 656–658
overview of, 641–645
recruitment of members, 647
resources, 660
termination of therapy and, 689
topics for, 648
women-only groups, 656

HBO. See Hyperbaric oxygen (HBO) prophylactically
Head and neck squamous cell carcinoma (HNSCCa). See also Oral cancer definition of, 263
Head and Neck Survey (H&NS; Gliklich, Goldsmith, & Funk), 700
Healing and the Mind (Moyers), 7
Health, WHO definition of, 5
Health-oriented model of care, 6-8
Hearing loss, 147, 368, 383, 414, 417, 602
Heat and moisture exchange (HME) systems
future developments for, 518
overview of, 509–515
pulmonary function assessment and, 508
tracheoesophageal puncture (TEP) voice prosthesis and, 444–445, 497
voicing problems and, 514
Hemilaryngectomy, 228, 328–329
History of Artificial larynx (AL). See also Artificial larynx (AL)
electronic larynx, 35–36
illustrations of, 41–42, 44–48
overview of, 30–36, 549–551
timeline of, 36–49
History of laryngectomy procedure. See also Laryngectomy
biopsy and, 26, 28
description of procedure, 20–23
justification for surgery, 25–26
life prolongation and, 24, 30
overview, 19
postoperative treatment, 26
timing of surgery and, 23–25
treatment advances timeline, 27–30
Holistic approach, 724–725
Homecoming preparation, 369–370
Hospital-based laryngectomy support groups, 652–655
Humiliation, 360
Hunterian Society of London, 27
Hyperbaric oxygen (HBO) prophylactically, 281, 283
Hypopharyngeal stricture, 614, 616

IAL. See International Association of Laryngectomees (IAL)
ICF. See International Classification of Functioning (ICF)
ICIDH. See International Classification of Impairments, Disabilities, and Handicaps (ICIDH)
IMO. See Injection method for obstruents (IMO)
Imperial Academy of Sciences, 32
Implant-supported prosthesis, 297–299, 587
Implanted artificial larynxes (AL), 579–580
IMSV. See Injection method for sonorants and vowels (IMSV).
Indwelling voice prostheses. See Tracheoesophageal puncture (TEP) voice prosthesis.
Informed consent, 707
Inhalation method
  esophageal speech training and, 675
  latency and, 413
  nasal resonance, 415
  overview of, 392–393
  teaching of, 407–408
  voice quality and, 411–412
InHealth Technologies, 494
Injection method for obstruents (IMO)
  articulation and, 413
  esophageal speech training and, 675
  evaluation of, 676
  latency and, 413
  multiple injections, 417
  nasal resonance and, 415
  overview of, 392
  teaching of, 394–402
  voice consistency and, 409
  voice versus unvoiced obstruents and, 414
Injection method for sonorants and vowels (IMSV)
  esophageal speech training and, 675
  evaluation of, 677
  latency and, 413
  multiple injections, 417
  nasal resonance and, 415
  overview of, 392
  teaching of, 402–407
  voice consistency and, 409
Intelligibility. See Vocal intelligibility
Intensity. See Vocal intensity
Interim obturator, 288
International Association of Laryngectomees (IAL),
  61, 370, 373, 633, 634, 652, 660, 691
International Classification of Functioning Disability and Health (ICIDH–2), 7
International Classification of Functioning (ICF), 7
International Classification of Impairments, Disabilities, and Handicaps (ICIDH), 7
International Medical Congress, 24
Intimacy, QOL and, 5
Intraoral prosthetics, 335–337
Inventory of Communication Attitudes, 98
Iron–deficiency anemia, 263
Isolation, 11, 71–72, 641, 644–645, 648
Jejunum free flap, 248–250
Jitter, 200, 206–209, 303
Journal of Laryngology and Rhinology, 23
Journal of the Acoustical Society of America, 35
Journal of the American Medical Association, 35, 40
Kay Elemetrics, 304, 685
Keratosis, 200, 205
Kett Engineering Corporation, 36, 44
Langenbeck Clinic, 21
LARKEL laryngectomy snorkel device, 636
Laryngectomy
  justification for surgery, 25–26
  life prolongation and, 24, 30
  postoperative treatment historically, 26
  rehabilitation success and, 10
  timing of surgery, 23–24
Laryngopharyngectomy, 239, 241, 241–242
Laryngopharyngeosophagectomy, 239
Laryngoxerosis, 200
Lateral thigh free flap, 251–252
Leakage, 437, 455, 465, 467, 468–469, 487, 603
Let's Face It: A Network for People with Facial Differences, 655, 660
Leukoplakia, 200
Listeners
  esophageal speech (ES) and, 387
  quality of speech and, 669
Listening, 358
Living arrangements, 146–147
Local flaps, 166
Loudness. See Vocal loudness
Macrostoma, 487, 495
Magnetic resonance imaging (MRI), 148, 272, 317
Mandibular surgery, 276–277
Manhattan Eye, Ear, and Throat Hospital, 39
Massachusetts Eye and Ear Infirmary, 549–550
Maxillofacial rehabilitation
  chemotherapy and, 274
  clinical staging and, 264–266
  communication rehabilitation, 299–306
  defect obturation, 275–276
  dentistry and, 277–280, 282, 285
  functional assessment of patients needing, 307–308
  implant-supported prosthesis, 297–299
  oral cancer management and, 267–277
  oral cancer overview and, 263–264
  osteoradionecrosis (ORN) and, 280–282
  overview of, 274
  posttreatment consequences of maxillary surgery and, 274
prosthetic management, 282–293
radiation therapy and, 274, 280–282
soft palate defect prosthetic rehabilitation, 294, 296
surgery and, 274, 276–277
therapeutic limitations and, 266
tongue defect reconstruction, 295–296
Mayo Clinic, 35
Mayo Clinic Postlaryngectomy Questionnaire, 104
MBS. See Modified barium swallow (MBS)
Medic-Alert bracelet, 373
Metastasize, 197
Microstoma, 487, 494–495
Mid-sized glottic cancer, 183–184. See also Oral cancer
Modified barium swallow (MBS), 325, 485
Mountain Precision Manufacturing, 575
Mouth surgery, 276–277
Mouth-type artificial larynxes (AL), 576–579
MRI. See Magnetic resonance imaging (MRI)
Mucositis, 204
Myotomy, 490, 536
Myonucleus, 536
Nasalance, 304
Nasometer, 304
National Commission for the Protection of Human Subject of Biomedical and Behavioral Research, 707–708
“Nature and Cause of Pulmonary Affections Produced by Bilateral Vagal Section” (Weir), 21
Near-total laryngectomy (NTL), 230–231
Neck-type artificial larynxes (AL), 551–554, 574–576, 577, 585
Needs communication, 716–718
Neoglottic tonicity, 616
Netherlands Cancer Institute, 474
New Voice Club, 633, 651–652, 691
Non-indwelling voice prostheses. See Tracheoesophageal puncture (TEP) voice prosthesis
Nonsurgical treatment of laryngeal carcinoma. See also Conservation laryngectomy procedures;
Surgery
chemotherapy, 202–204
malignancy development and, 197–198
organ preservation and, 105
perceived voice attributes and, 210
posttreatment management, 211
radiation therapy, 201–202
vocal tract effects of, 204–210
Nonverbal behaviors, 416–418, 424–425, 564, 675
Nonvocal communication, 81, 86
NTL. See Near-total laryngectomy (NTL)
Nu-Voice Club, 70
Obturation. See Defect obturation
Occlusive spasm, 534
Occupational functioning, QOL and, 5
Oncogenes, 197
One-to-one peer support, 656
Oral articulatory evaluation, 305–306
Oral cancer. See also Early glottic cancer; Glottic cancer; Mid-sized glottic cancer; Supraglottic cancer; Treatment options chemotherapy and, 266, 274
clinical staging, 264–266
demographics and incidence of, 263
diagnosis and, 267–272
etiology, 263–264
examples of, 272
imaging and, 272
management of, 267–277
overview of, 263
palliative treatment, 273
prognosis and, 273
radiation therapy and, 266, 274
rehabilitation, 273
risk factors for, 263–264
squamous cell carcinoma and, 267
surgery and, 266, 274
therapeutic modality limitations, 266
treatment sequence, 270
tumor, node, and metastasis (TNM) and, 264–267
Oral-motor and communication function assessment, 301–306
Oral reading rate, 82
Oral Vibrator, 36, 42, 46
Organ preservation, 105–106
ORN. See Osteoradionecrosis (ORN)
Osteoradionecrosis (ORN), 280–282, 318, 338
Outcomes of speech rehabilitation. See also Treatment success communication proficiency, 81–84
overall communication functioning, 84–86
overview of, 77
prevalence of modes of alaryngeal communication, 77–81
speech acquisition, 94–96
Overarticulation, 561–563
Palliative treatment, 273
Partially edentulous individual, 290–291
Patient history, upper aerodigestive tract malignancy and, 145–147
PE. See Pharyngoesophageal (PE) spasm
Pectoralis major flap, 246–248, 278
Peer group support. See also Counseling; Family; Group treatment models
alaryngeal speech activities, 635
altruism and, 630
attendance and, 631
benefits of, 627–629
counseling and, 637
facilitator role in group speech therapy, 631–632
goals and, 632
mechanics of, 629–631
metacommunication skills and, 635–636
one-to-one peer support, 656
overview of, 627
overview of speech therapy groups, 632–635
psychological adaptation and, 628, 636
social laryngectomy clubs, 633–635
topics for group therapy, 635–637
universality and, 630
Pharyngeal wall resection, 331
Pharyngocutaneous fistula, 490
Pharyngoesophageal (PE) segment function
alaryngeal voice generation and, 523–524
cricopharyngeal spasm and, 533–535
esophageal speech (ES) and, 523–526, 529–534
myotomy of phyrngeal constrictor muscles, 536
neurological control of, 527–528
overview of, 523
PE spasm, 64, 533–537
pharyngeal plexus neurectomy, 536
structure of, 524–527
surgical and medical treatment for voice failure, 535–537
TE speech and, 523, 538, 679–680
tracheoesophageal puncture (TEP) and, 523, 528–529
Pharyngoesophageal (PE) spasm, 64, 533–537
Phonatory evaluation, 302–303
Pitch. See Vocal pitch
Plummer-Vinson syndrome, 263
Pneumonia, 21, 29, 30, 93, 146
Postfitting aphonya, 485, 489–490
Postoperative inpatient counseling, 368–369, 373
Postsurgery outpatient counseling, 370, 374
Postures for assistance in swallowing, 326, 335
Primary closure, 165
Prosthetic management
for edentulous and mandibulectomized individual, 293–294
for edentulous individual, 291–292
implant-supported prostheses, 297–299
for partially edentulous individual, 290–291
for partially edentulous mandibulectomized individual, 292–293
presurgical dental assessment and management, 282, 286
prosthetic rehabilitation, 287–290
surgical obturators, 275–276, 287–290
swallowing disorders and, 335–337
Provox extended-wear voice prosthesis, 483
Provox HME device, 514
Provox Stomafilter System, 497
Psychological issues. See also Self-esteem
anxiety, 12, 641, 646, 649, 711
attitude toward health care professionals and, 714–716
coping and, 649–650
depression, 71, 72, 641, 649, 710, 711, 724, 744
intervention and, 642
isolation, 11, 71–72, 641, 644–645, 648
overview of psychiatric morbidity, 5–7
peer support and, 628
psychological distress, 130, 646
psychosocial distress, 6, 130, 641, 720, 726
quality of life (QOL) and, 710–712
screening for, 720–722
treatment success and, 10–11
verbal communication and, 5, 11–12, 595, 636
Psychosocial Adjustment to Illness Scale (PAIS; Derogatis & Lopez), 103
Pulmonary function, 507–510, 600–602
Quality of life (QOL)
adaptation of rehabilitation and, 723
artificial larynx (AL) and, 727
assessment of, 699–703, 718–722
coping styles and, 713–714
decision making and, 712–713
definitions of, 699, 743
dimensions of, 5
educational materials and, 709
emotional adjustments and, 357
ethical perspective and, 707–708
future research directions, 725–729
group treatment models and, 646
health assessment and, 699–703
holistic approach and, 724–725
impact of disease on, 12–13, 641, 643, 703–706
isolation and, 11
needs communication and, 716–718
outcome measures and, 701
overview of, 699
patient attitudes about health professionals and, 714–716
patient knowledge and, 708–710
patient participation in rehabilitation and, 723–724
physical disfigurement and, 361
physical problems and, 712
psychosocial difficulties and, 710–712
reasons for patient nonassertion about, 708–718
sexuality and, 5
speech-language pathologists and, 706–707, 711, 718–725
successful total rehabilitation and, 97
survival duration and, 8
treatment options and, 155–156, 273
treatment success and, 104–109, 748
Radial forearm flap, 167–168, 250–251
Radiation therapy
alaryngeal speech development and, 597–599
brachytherapy, 159–160
dental issues and, 318
depression and, 711
dysphagia and, 595, 597, 601–602
limitations of, 266
overview of, 201–202
posttreatment management of vocal symptoms, 211
supraglottic tumors and, 227
surgery compared with, 156–157
swallowing disorders and, 337–340
tracheoesophageal puncture (TEP) voice prosthesis and, 437, 475
Rand Development Corporation, 45
Rate. See Speech rate
Reconstruction
cervical rotation flaps and, 241–242
deltoidal flap (DP) and, 243–245
dentistry and, 277–280, 282, 285
extended laryngectomy and, 239–241
gastric pull-up procedure, 245–246
jejunal free flap and, 248–250
lateral thigh free flap and, 251–252
overview of, 239–241
pectoralis major flap and, 246–248, 278
radial forearm free flap and, 250–251
reconstructive options, 162–168
supracricoid partial laryngectomy with reconstruction (SCPL) and, 232
swallowing and, 239
tissue overview, 252–254
verbal communication and, 184, 254–258
Regional flaps, 166–167
Rehabilitation in head and neck cancer. See also Counseling; Group treatment models; Maxillofacial rehabilitation; Peer group support; Speech-language pathologists; Treatment success
biopsychosocial model, 7–9, 724–725, 743–745
clinical program expansion, 740–741
current status of, 739–740
emergent themes in, 750
emotional support and, 356–360
facilitation of, 747–750
goals and, 359–360, 632, 668, 670–680
grief cycle and, 70–72, 357
lifestyle alteration and, 749
multidimensional constructs, 743–745
new care paradigm, 745–746
overview of, 739
programs of care, 741–742
psychological issues, 744, 750
psychosocial impact of cancer, 746–747
support groups for, 652–656
Resonatory evaluation, 303–305
Respiratory issues. See Total laryngectomy respiratory consequences
Romet, 575
Salivary flow. See Xerostomia
Scintigraphy, 319–320
SCPL. See Supracricoid partial laryngectomy with reconstruction (SCPL)
Secondary TEP voice restoration, 462, 465
Self-esteem
as affected by disease, 12
alaryngeal speech development and, 595
coping and, 649
friendship maintenance and, 366
head and neck cancer and, 641
patient attitude toward health care providers and, 716
physical disfigurement and, 361
Self-Evaluation of Communication Experiences After Laryngectomy (SECEL; Blood), 103
Self-induced isolation. See Isolation
Sexuality, 5
SGL. See Supraglottic laryngectomy (SGL) procedure
Shimmer, 200, 206–209, 303
Siemens, 575
Singer and Blom duckbill prosthesis, 438
Sleep disturbances, 505, 711, 716
Smell sense, 602
Smoking and tobacco, 197, 200, 205, 263, 600, 749
Social context of communication, 115
Social isolation. See Isolation
Social laryngectomy clubs, 633–635
Soft palate defect, 294, 296
Speech. See Verbal communication; headings beginning Voice
Speech-language pathologists. See also Accountability in alaryngeal speech rehabilitation; Counseling; specific types of alaryngeal speech
conversation starters, 375–376
counseling and, 318–319, 340, 355–356
functional assessment of patients needing maxillofacial prosthodontics and, 307
homecoming preparation, 369–370
hospital-based laryngectomy support groups and, 652–653
information delivery and, 362–363
intraoral prosthetics and, 336–337
lesson planning, 680, 682–688
organ-preservation treatments and, 340
postoperative inpatient counseling and, 368–369, 373
postoperative outpatient counseling, 370, 374
posttreatment intervention and, 319
preoperative counseling and, 366–368, 372, 458
quality of life (QOL) and, 706–707, 711, 718–725
role of, 300, 355–356, 667
swallowing disorders and, 317
termination of therapy and, 689, 691
therapy logs and, 688–689
therapy session elements, 686–688
tracheoesophageal puncture (TEP) voice prosthesis and, 458–461, 483
trust establishment and, 360–362
Speech rate, 69–70, 382, 415–416, 422, 448, 670, 675
Spirituality, 5
Split-thickness skin grafts, 165–166
SPOHNC. See Support for People with Oral and Head and Neck Cancer (SPOHNC)
Spouses, 363–366
Squamous cell carcinoma, 267
St. Boniface Hospital, 656
Stages of loss, 70–72
Stigmatization, 746–747
Stomal stenosis and irregularity, 616–617
Stomatitis, 204
Stridor, 199
Stutter, 98, 368
Successful total rehabilitation, 96–102, 109
Suffocation, 23
Suicide, 357, 716
Support for People with Oral and Head and Neck Cancer (SPOHNC), 655, 660
Supracricoid partial laryngectomy with reconstruction (SCPL), 231–232
Supraglottic cancer, 185–189. See also Oral cancer
Supraglottic laryngectomy (SGL) procedure, 226–228, 329–330
Surgery. See also Nonsurgical treatment of laryngeal carcinoma; Reconstruction
alaryngeal speech development problems and, 603–605
dentistry and, 277–280, 282, 285
dysplasia and, 173–184
eye glottic cancer and, 173–184
limitations of, 266
mandibular surgery, 276–277
maxillary surgery, 274–275
mid-sized glottic cancer and, 183–184
mouth surgery, 276–277
overview of, 160–162
postoperative inpatient counseling and, 368–369, 373
preoperative counseling, 366–368, 372, 458
radiation therapy compared with, 156–157
supraglottic cancer and, 185–189
supraglottic tumors and, 227
swallowing disorders and, 331–335
tongue surgery, 276
tracheoesophageal puncture (TEP), 458–461, 463–464
vocal fold atypia and, 173–184
Surgical reconstruction. See Reconstruction
Survivability, 8, 93–94, 267
Swallowing disorders
aspiration and, 329
counseling and, 318–319, 340
exercises for, 329, 330, 334, 335
hemilaryngectomy and, 328–329
intraoral prosthetics, 335–337
maneuvers for altering swallow physiology, 327
normal swallowing, 320–325
obdurators and, 337
pharyngeal wall resection and, 331
posttreatment intervention and, 319–320
postures for assistance in, 326, 335
pretreatment rehabilitation considerations, 317–318
radiation therapy and, 337–340, 601–602
radiographic evaluation and, 325–328
rationales for appropriate bolus types, 327
scintigraphy and, 319–320
supracricoid partial laryngectomy with reconstruction (SCPL) and, 232
supraglottic laryngectomy and, 329–330
supraglottic laryngectomy (SGL) procedure and, 227–228
surgical treatment and, 161, 189, 239, 331–335
swallowing evaluation, 306
total laryngectomy and, 330–331
ultrasound and, 319–320
videoendoscopy and, 319–320
videofluoroscopy and, 319–320
Swimming, 636
Syphilis, 20, 28

TE. See Tracheoesophageal (TE) speech
Teeth, 161
Telephone communication, 84
Templin-Darley Tests of Articulation (Templin & Darley), 305
TEP. See Tracheoesophageal puncture (TEP)
Termination of therapy, 689, 691
Therapy logs, 688–689
Therapy report outline, 690
Thrush, 204
Total laryngectomy, 330–331, 603
Total laryngectomy respiratory consequences
coughing, 505
heat and moisture exchange (HME) system and, 508–515, 518
medical treatment and, 515–518
overview of, 505–506
phlegm production, 505–506
pulmonary function assessment, 507–510
stoma breathing effects, 506–507
Total laryngopharyngectomy, 239, 241–242, 604
Total laryngopharyngoesophagectomy, 604
Tracheoesophageal puncture (TEP), 62, 79, 95, 106, 256–257
Tracheoesophageal puncture (TEP) voice prosthesis
acquisition success factors, 456, 458
alcoholism and, 437
candida albicans and, 455, 467–468, 474, 493
candidate for, 436–437, 599
care and cleaning of, 443, 473, 484–485
care for, 436–437, 599
candidacy for, 436–437, 599
care and cleaning of, 443, 473, 484–485
chronic peritracheal and, 436
complications associated with, 434, 436
device selection, 442
disappearance of, 470–471
delayed dysphonia and, 599
delayed postfitting aphonia and, 486
duration insufficiency, 488
dysphonia and, 491–492
dysphonia and, 491–492
emergency speech, 490–491
gastric air excesses, 498
granuloma, 488, 497–498, 610
leakage, 487, 492–493
macrostoma, 487, 495
microstoma, 487, 494–495
overview of voice problems, 473–475, 483–485
postfitting aphonia and, 485, 486, 489–490
procedure candidates, 483, 484–485
prosthesis deterioration and, 493–494
radiation therapy and, 598
speech quality, 488–489
troubleshooting guide, 486–489
valve problems, 495–497
Tracheoesophageal (TE) speech. See also Verbal
communication
articulation and, 66, 680
assessment of, 615, 679–680, 681
average communication profile score and, 86
Botox and, 608, 613
communication problems and, 84–85
compared with other types of alaryngeal speech, 61–62
consistency of voicing, 670
cricopharyngeal spasm and, 533–535, 608
descriptive aspects of, 118
distractors and, 63–65
fluency protocol, 615
fundamental frequency and, 119–121
intelligibility, 83, 84, 447–448, 475
long-term effects of, 106–107
occlusive spasm and, 534
oral reading rate for, 82, 83
overview of, 79–81
patient training in, 446–448
pharyngoesophageal (PE) segment and, 523, 679–680
placement of speech aids and, 63
preference rate for, 80–81
problems related to, 609–612
pulmonary function and, 601
radiation therapy and, 598–599
reconstruction and, 256–257
spasm and, 533–535, 608, 613–614
speech therapy, 471–473
statistics on usage of, 61–62
vocal intensity and, 121–122
vocal loudness and, 67, 448, 610
vocal pitch and, 447–448
voice quality and acceptability and, 123–124, 499
Training
for artificial larynx (AL), 556–564
for esophageal speech (ES), 384–386, 388–390, 418–419, 606, 675, 679
feedback and, 389, 419–421, 684–685
lesson planning, 680, 682–688
for tracheoesophageal puncture (TEP) voice prosthesis use, 443, 473, 607
for tracheoesophageal (TE) speech, 446–448
variable practice and, 685–686
Treatment options
free flap procedures, 167–168
limitations of, 266
local flaps, 166
overview of, 155
primary closure, 165
principles of treatment, 155–156
QOL and, 155–156
radiation therapy, 156–160
reconstructive options, 162–168
regional flaps, 166–167
split-thickness skin grafts, 165–166
surgery, 160–162
Treatment satisfaction, QOL and, 5
Treatment sequence, 270
Treatment success. See also Outcomes of speech rehabilitation; Quality of life (QOL)
artificial larynx and, 566–567
biopsychosocial model and, 743–745
communication satisfaction and, 98–100
counseling and, 100–102, 108
definition of, 5
factors contributing to, 129–133
gender and, 100–102
laryngectomy and, 10
organ preservation and, 105–106
overview of, 93
patient attitude and participation and, 102–103, 108–109, 723–724
patient history and, 146–147
psychological issues and, 6, 10–11, 130
self-esteem and, 355
speech acquisition and, 94–96
successful total rehabilitation, 96–102, 109
survivability and, 8, 93–94, 267
Trismus, 148, 334, 338
Trust establishment, 360–362
Tumor, node, and metastasis (TNM), 264–267
Ultrasound, 319–320
UNI Manufacturing Company, 575
Universally, 630
University Göttingen, 21
University of Sydney, 37
University of Washington QOL Questionnaire (UW–QOL; Hassan & Weymuller), 700
Upper aerodigestive tract malignancy
clinical examination, 147–150
overview of, 145
patient history and, 145–147
posttreatment follow-up, 150–151
pretreatment evaluation, 145–150
rehabilitation success and, 146
VA Rehabilitation Research and Development Grant, 580
Verbal communication. See also Artificial larynx (AL); Communication; Esophageal speech (ES); Tracheoesophageal (TE) speech; headings beginning Voice
aging and, 200
chemotherapy and, 204–205
counseling and, 299
endoscopic technique and, 179–182, 188–189
glottic reconstruction and, 184
jitter and, 200, 206–209, 232
laryngeal carcinoma and, 198–201
low voice, 257
nasalance and, 304
near-total laryngectomy (NTL) and, 231
nonsurgical treatments and, 204–210
oral communication assessment, 299–300
oral–motor and communication function assessment and, 301–306
outcome measures, 306–308
psychiatric morbidity and, 5, 11–12
reconstruction and, 184, 254–258
shimmer and, 200, 206–209, 232
speech–language pathologists and, 300, 307
supracricoid partial laryngectomy with reconstruction (SCPL) and, 232
surgery treatment and, 161
vertical partial laryngectomy (VPL) and, 229
voice and speech rehabilitation, 10
voice consistency and, 408–411
Vertical partial laryngectomy (VPL), 228–229
Videoendoscopy, 319–320
Videofluoroscopy, 304, 319–320, 484
Videonasendoscopy, 340
Visual acuity, 602
Vocal fold atypia
disease presentation, 173
endoscopic technique and, 178–179
management philosophy, 173–176
vocal outcome and, 179–182
Vocal intelligibility
artificial larynx (AL) and, 82, 83, 566, 578, 581, 582, 584
esophageal speech (ES), 82–84, 384–385, 673
radical surgery and, 603
tracheoesophageal (TE) speech and, 83, 84, 447–448, 475
voice and speech perception, 122–124
Vocal intensity, 121–122
Vocal loudness
alaryngeal speech and, 63
artificial larynx (AL) and, 67–68, 581
esophageal speech (ES) and, 67–68, 423–424, 675
tracheoesophageal (TE) speech and, 67, 448, 610
Vocal pitch, 69, 423, 447–448, 581
Vocophone, 40
Voice and speech perception. See also Verbal communication
aging and, 200
descriptive aspects of alaryngeal voice and speech, 118–127, 131–132
durational measures and, 122
fundamental frequency and, 119–121
intelligibility and, 122–124
intensity and, 121–122
interrelationships of physical and perceptual measures, 126–127
multidimensional structure of alaryngeal speech, 127–128
nature of alaryngeal speech and, 116–117
nonsurgical treatment and, 210
overview of, 115–116
participation restrictions, 115–116
rehabilitative success and, 129–133
vocal intensity and, 121–122
voice quality and acceptability, 123–125
Voice boxes. See Artificial voice boxes
Voice consistency, 408–411
Voice quality and acceptability, 123–125, 499
Voice rehabilitation, nonsurgical treatment of laryngeal carcinoma and, 197–198
VPL. See Vertical partial laryngectomy (VPL)
Vulnerability, 650, 726
W.M. Keck Neural Prosthesis Research Center, 585
Western Electric Company, 34, 35, 39, 40–42, 47, 574
Why Me? (Gargan), 369
World Health Organization (WHO), 115, 699, 701, 743
Xerostomia, 159, 280, 338